GRK1 — G protein-coupled receptor kinase 1

The GRK1 gene provides instructions for making a protein called rhodopsin kinase, which is essential for normal vision, particularly in low-light conditions. This protein is found in the rod cells of the retina, the light-sensitive tissue at the back of the eye. When light enters the eye, it activates a protein called rhodopsin in the rod cells, starting a signal that travels to the brain to produce an image. Once the signal is sent, rhodopsin must be quickly turned off so the eye can respond to the next flash of light. The GRK1 protein is responsible for starting this "turn-off" process. When there are harmful changes (mutations) in both copies of the GRK1 gene, the rhodopsin kinase protein does not work correctly or is missing. As a result, the light-activated rhodopsin stays turned on for too long. This delay in turning off the signal means the rod cells take much longer to recover and become sensitive to light again. For patients, this causes a condition called Oguchi disease, a type of congenital stationary night blindness. People with this condition have difficulty seeing in dim light or the dark from birth, and it can take them hours to adjust to the dark, compared to minutes for someone without the condition. Oguchi disease is inherited in an autosomal recessive pattern, meaning a person must inherit two mutated copies of the gene (one from each parent) to have the condition. Parents who carry one mutated copy are typically unaffected. Importantly, Oguchi disease is "stationary," meaning the night blindness does not get worse over time, and it does not typically lead to severe vision loss or blindness. Day vision, color vision, and visual sharpness usually remain normal, though some patients may have nearsightedness.

Gene description: GRK1, also known as rhodopsin kinase, phosphorylates rhodopsin to initiate its deactivation.

Patient and family guide: The GRK1 gene provides instructions for making a protein called rhodopsin kinase, which is essential for normal vision, particularly in low-light conditions. This protein is found in the rod cells of the retina, the light-sensitive tissue at the back of the eye. When light enters the eye, it activates a protein called rhodopsin in the rod cells, starting a signal that travels to the brain to produce an image. Once the signal is sent, rhodopsin must be quickly turned off so the eye can respond to the next flash of light. The GRK1 protein is responsible for starting this "turn-off" process. When there are harmful changes (mutations) in both copies of the GRK1 gene, the rhodopsin kinase protein does not work correctly or is missing. As a result, the light-activated rhodopsin stays turned on for too long. This delay in turning off the signal means the rod cells take much longer to recover and become sensitive to light again. For patients, this causes a condition called Oguchi disease, a type of congenital stationary night blindness. People with this condition have difficulty seeing in dim light or the dark from birth, and it can take them hours to adjust to the dark, compared to minutes for someone without the condition. Oguchi disease is inherited in an autosomal recessive pattern, meaning a person must inherit two mutated copies of the gene (one from each parent) to have the condition. Parents who carry one mutated copy are typically unaffected. Importantly, Oguchi disease is "stationary," meaning the night blindness does not get worse over time, and it does not typically lead to severe vision loss or blindness. Day vision, color vision, and visual sharpness usually remain normal, though some patients may have nearsightedness.

Gene function: GRK1 is a key enzyme in the visual phototransduction cascade, responsible for phosphorylating photoactivated rhodopsin. This phosphorylation is the initial step in the deactivation of rhodopsin, allowing the visual system to recover quickly after light exposure and adapt to changes in light intensity. Defective GRK1 leads to prolonged activation of rhodopsin, impairing dark adaptation and causing night blindness.

Protein structure: The GRK1 gene encodes a protein of 562 amino acids, belonging to the G protein-coupled receptor kinase (GRK) family. The protein structure consists of three main domains: an N-terminal domain, a central catalytic kinase domain, and a C-terminal domain. The N-terminal domain is involved in receptor recognition and binding, ensuring specificity for rhodopsin. The central kinase domain is responsible for the ATP-dependent phosphorylation of the target serine and threonine residues on rhodopsin. The C-terminal domain of GRK1 contains a CAAX motif (where C is cysteine, A is an aliphatic amino acid, and X is any amino acid), which undergoes post-translational modification. Specifically, it is farnesylated, a type of lipid modification that anchors the kinase to the disc membranes of the rod outer segments, where rhodopsin is located. This membrane anchoring is crucial for the efficient interaction between GRK1 and its substrate. The protein functions as a monomer and does not assemble into larger multi-subunit complexes for its primary activity.

Molecular function: The GRK1 gene encodes G protein-coupled receptor kinase 1, also known as rhodopsin kinase. This enzyme is a critical component of the phototransduction cascade in rod photoreceptors. Its primary molecular function is to phosphorylate light-activated rhodopsin (R*), a G protein-coupled receptor. Upon photon absorption, rhodopsin undergoes a conformational change to its active state, which then activates the G protein transducin, initiating the visual signal. To terminate this signal and allow the photoreceptor to recover and respond to subsequent light stimuli, R* must be rapidly deactivated. GRK1 specifically recognizes and binds to the active conformation of rhodopsin, phosphorylating multiple serine and threonine residues on its intracellular C-terminal tail. This phosphorylation creates a high-affinity binding site for the protein arrestin (encoded by the SAG gene). The binding of arrestin to phosphorylated rhodopsin sterically blocks further interaction with transducin, effectively quenching the phototransduction cascade. This rapid deactivation is essential for the temporal resolution of vision and for preventing the continuous activation of the pathway, which could lead to photoreceptor damage. Thus, GRK1 plays a pivotal role in the recovery phase of the rod photoresponse and in light adaptation.

Expression pattern: The GRK1 gene is highly and specifically expressed in the retina, particularly in the photoreceptor cells. In humans and most mammals, GRK1 expression is predominantly localized to rod photoreceptors, where it plays a critical role in the phototransduction cascade. However, the expression pattern can vary among species; for example, in mice and humans, GRK1 is primarily found in rods, whereas in some other species, it may also be expressed in cone photoreceptors. Within the rod photoreceptors, the GRK1 protein is primarily localized to the outer segments, where the phototransduction machinery is concentrated. The expression of GRK1 is tightly regulated to ensure the proper timing and magnitude of rhodopsin deactivation. There are no significant tissue-specific isoforms outside the retina, underscoring its specialized role in vision.

Mutation spectrum: The mutation spectrum of the GRK1 gene includes a variety of pathogenic variants, primarily consisting of missense, nonsense, frameshift, and splice-site mutations, as well as small deletions. These mutations are distributed across the gene, affecting different functional domains of the protein, such as the kinase domain. The majority of these variants lead to a loss of function, either by producing a truncated, unstable protein or by directly impairing the kinase activity required for rhodopsin phosphorylation. While Oguchi disease is rare globally, it has a higher prevalence in the Japanese population, where specific founder mutations have been identified. For instance, certain missense mutations and small deletions are more frequently observed in Japanese patients. In other populations, such as in South Asia and Europe, different private or recurrent mutations have been reported, often in consanguineous families. The total number of known pathogenic variants is relatively small, reflecting the rarity of the condition.

Pathogenic variants: 1. p.Ser205* (c.614C>A) - A nonsense mutation identified in a consanguineous Pakistani family, leading to premature protein truncation and typical Oguchi disease. 2. c.1607_1610delCGGA - A small deletion resulting in a frameshift, reported in Polish and other European patients, causing loss of function and Oguchi disease. 3. p.Pro391His - A missense mutation identified in siblings with Oguchi disease, affecting a conserved residue and impairing protein function. 4. p.Leu308Pro (c.923T>C) - A missense mutation found in a Turkish family, located in a highly conserved region, leading to Oguchi disease. 5. Exon 3 deletion - A larger structural variant reported in some cases, leading to a variant form of Oguchi disease without the typical Mizuo-Nakamura phenomenon.

Clinical significance: Mutations in the GRK1 gene are primarily associated with Oguchi disease type 2, a rare autosomal recessive form of congenital stationary night blindness (CSNB). Clinically, patients present with non-progressive night blindness from early childhood. A hallmark feature of Oguchi disease is the Mizuo-Nakamura phenomenon, where the fundus exhibits a golden-yellow or grayish-white metallic sheen in the light-adapted state, which disappears and returns to a normal appearance after prolonged dark adaptation (typically 2 to 3 hours). The severity of the disease is generally mild, as it is non-progressive and visual acuity, visual fields, and color vision typically remain normal. However, patients may experience significantly delayed dark adaptation, taking hours to reach normal scotopic thresholds. Some patients may also present with associated features such as myopia and nystagmus. While the condition is stationary, the profound night blindness can impact daily activities in low-light environments.

Inheritance: Autosomal Recessive

Chromosomal location: 13q34

Genotype-phenotype correlations: Genotype-phenotype correlations in GRK1-associated Oguchi disease are generally consistent, with biallelic loss-of-function mutations leading to the classic Oguchi phenotype. Most pathogenic variants, including missense, nonsense, and frameshift mutations, result in a significant reduction or complete loss of GRK1 kinase activity. This biochemical defect directly correlates with the clinical manifestation of prolonged dark adaptation and the Mizuo-Nakamura phenomenon. While the core phenotype of stationary night blindness is uniform, there can be some variability in the presence of secondary features such as myopia or nystagmus. However, these variations do not strongly correlate with specific mutation types or locations within the gene. The non-progressive nature of the disease remains a constant feature across different GRK1 genotypes, distinguishing it from progressive retinal degenerations like retinitis pigmentosa.

Research and therapeutic approaches: Currently, there are no approved targeted therapies or cures for GRK1-associated Oguchi disease. Management is primarily supportive, focusing on addressing any associated refractive errors, such as myopia, with corrective lenses. Patients are also counseled on the stationary nature of the disease and provided with strategies to cope with night blindness, such as using adequate lighting and allowing extra time for dark adaptation when moving from bright to dim environments. Research into therapeutic approaches is ongoing, with gene therapy being a prominent area of investigation. Animal models, particularly Grk1 knockout mice, have shown that adeno-associated virus (AAV)-mediated delivery of a functional GRK1 gene can restore normal rod deactivation and protect against light-induced retinal damage. While these preclinical results are promising, clinical trials for GRK1 gene therapy in humans have not yet been initiated. Interestingly, the GRK1 promoter itself is widely used in other retinal gene therapy trials (e.g., for RPGR) due to its high efficiency in driving gene expression specifically in photoreceptors.

Diagnostic testing: Diagnostic testing for GRK1-associated Oguchi disease typically involves a combination of clinical evaluation and genetic testing. Clinically, the diagnosis is strongly suggested by the presence of congenital stationary night blindness and the characteristic Mizuo-Nakamura phenomenon observed during fundus examination. Electroretinography (ERG) is also crucial, showing an absent or severely reduced rod response under standard dark adaptation, which may normalize after prolonged dark adaptation (several hours). Genetic testing confirms the diagnosis by identifying biallelic pathogenic variants in the GRK1 gene. This can be achieved through targeted gene panels for inherited retinal diseases (IRDs) or congenital stationary night blindness, whole exome sequencing (WES), or whole genome sequencing (WGS). Genetic counseling is recommended for affected individuals and their families to discuss the autosomal recessive inheritance pattern, the non-progressive nature of the disease, and the implications for family planning. Carrier testing for at-risk relatives can also be offered.

Animal models: Mouse models, particularly Grk1 knockout mice, have been instrumental in understanding the role of GRK1 in retinal function and disease. These models demonstrate that the absence of GRK1 leads to prolonged photoresponses in rod photoreceptors, as rhodopsin cannot be efficiently deactivated. This results in increased susceptibility to light-induced retinal degeneration. Studies using these mice have shown that the delayed recovery of the rod photoresponse mimics the clinical phenotype of Oguchi disease, characterized by prolonged dark adaptation. Additionally, animal models have been used to test gene therapy approaches. For instance, adeno-associated virus (AAV)-mediated delivery of the GRK1 gene has been shown to restore normal rod deactivation kinetics and protect against light-induced damage in Grk1 knockout mice. These models have also been crucial in evaluating the efficacy of different promoters, such as the GRK1 promoter itself, for targeting gene expression specifically to photoreceptors in both mice and non-human primates.

Population genetics: Oguchi disease caused by GRK1 mutations is a very rare condition globally, with an estimated prevalence of less than 1 in 1,000,000. However, it is notably more common in the Japanese population, where the disease was first described. This higher prevalence is attributed to founder effects, where specific mutations have been passed down through generations in a relatively isolated population. In other parts of the world, GRK1 mutations are extremely rare and are often identified in individuals from consanguineous families, where the likelihood of inheriting two copies of a rare recessive mutation is increased. Carrier frequencies in the general non-Japanese population are very low.

Selected references: 1. Azam M, et al. A novel mutation in GRK1 causes Oguchi disease in a consanguineous Pakistani family. Mol Vis, 2009. PMID: 19753316 2. Skorczyk-Werner A, et al. The first case of Oguchi disease, type 2 in a Polish patient with confirmed GRK1 gene mutation. Klin Oczna, 2015. PMID: 26349155 3. Cideciyan AV, et al. Null mutation in the rhodopsin kinase gene slows recovery kinetics of rod and cone phototransduction in man. Proc Natl Acad Sci U S A, 1998. PMID: 9419375 4. Oishi A, et al. Novel mutations in the GRK1 gene in Japanese patients With Oguchi disease. Am J Ophthalmol, 2007. PMID: 17765441 5. Yamamoto S, et al. Evaluation of the rhodopsin kinase gene in patients with retinitis pigmentosa. Exp Eye Res, 1997. PMID: 9268593